Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis
NCT05906433Phase 1Completed
- Sponsor
- Foundation for Orthopaedic Research and Education
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of bupivacaine in knee osteoarthritis (OA) (3 arms), sponsored by Foundation for Orthopaedic Research and Education. Primary endpoints: Time from procedure when postoperative status is considered success at 84 days and Visual Analog Scale for Pain at 84 days. Started Jun 2023; status: completed.
02
Drugs
bupivacaine
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05906433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05906433.